NDA 021818 · Romark
Alinia
Nitazoxanide · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 16, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 16, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
111
46 Phase 3, 8 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 2005 Original approval · Type 6 - New Indication (no longer used) · priority review LabelLetterReview
1 products under this application
- ALINIA · NITAZOXANIDE 500MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitazoxanide" as an intervention, any sponsor and status, largest first.
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- COVID-19 Prophylaxis South Africa (COVER HCW)Pivotal-lookingCompleted
University of Witwatersrand, South AfricaAcademic, hospital or other
NCT04561063 · 1,950 participants · Start Dec 8, 2020 · Primary completion Feb 28, 2022
Drug: Nitazoxanide; Sofosbuvir/Daclatasvir · For: Covid19; SARS-CoV Infection
Sites: Johannesburg, South Africa · 2 sites in all
- Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated InfluenzaPivotal-lookingCompleted
Romark Laboratories L.C.Industry
NCT01610245 · 1,941 participants · Start Mar 2013 · Primary completion Mar 2015
Drug: Nitazoxanide; Oseltamivir and 2 more · For: Influenza
Sites: Birmingham, Alabama; Dothan, Alabama; Hoover, Alabama · 167 sites in all
- Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus InfectionPivotal-lookingCompleted
Romark Laboratories L.C.Industry
NCT03605862 · 1,756 participants · Start Sep 11, 2018 · Primary completion Feb 4, 2019
Drug: Nitazoxanide; Placebo · For: Enterovirus; Rhinovirus
Sites: Birmingham, Alabama; Pelham, Alabama; Hot Springs, Arkansas · 45 sites in all
Romark Laboratories L.C.Industry
NCT04359680 · 1,407 participants · Start May 13, 2020 · Primary completion Apr 7, 2021
Drug: Nitazoxanide; Placebo · For: COVID-19; Viral Respiratory Illnesses
Sites: Hot Springs, Arkansas; Huntington Beach, California; Long Beach, California · 26 sites in all
- Early Life Interventions for Childhood Growth and Development In TanzaniaPivotal-lookingCompleted
Haydom Lutheran HospitalAcademic, hospital or other
NCT03268902 · 1,188 participants · Start Sep 5, 2017 · Primary completion Feb 28, 2020
Drug: Azithromycin Oral Liquid Product; Nitazoxanide Oral Suspension and 1 more · For: Malnutrition; Stunting; Cognitive Development and 1 more
Sites: Haydom, Tanzania
- A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated InfluenzaPivotal-lookingCompleted
Romark Laboratories L.C.Industry
NCT03336619 · 1,030 participants · Start Jan 17, 2018 · Primary completion Apr 17, 2019
Drug: Nitazoxanide; Placebo · For: Influenza
Sites: Alabaster, Alabama; Birmingham, Alabama; Hoover, Alabama · 38 sites in all
- Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19Pivotal-lookingCompleted
Romark Laboratories L.C.Industry
NCT04486313 · 935 participants · Start Aug 13, 2020 · Primary completion Feb 8, 2021
Drug: Nitazoxanide; Placebo · For: COVID-19
Sites: Fort Lauderdale, Florida; The Bronx, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amoebic dysentery.
Marie C, Petri WA · BMJ Clin Evid 2013 · Systematic Review
- Amoebic dysentery.
Mackey-Lawrence NM, Petri WA · BMJ Clin Evid 2011 · Systematic Review
- Drugs for treating giardiasis.
Granados CE, Reveiz L, Uribe LG, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Systematic Review
- The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abuelazm M, Ghanem A, Awad AK, et al. · Clin Drug Investig 2022 · Meta-Analysis, Systematic Review
- NTZ for cryptosporidiosis.
· GMHC Treat Issues 1996 · Clinical Trial, Newspaper Article
- Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela S, Bosch B, Hill A, et al. · J Antimicrob Chemother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Romark
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.